Sách chuyên ngành Y Dược: Bone Cancer (Ung thư xương)

DOMINIQUE HEYMANN

BONE CANCER

(UNG THƯ XƯƠNG)

PUBLISHER: ELSEVIER ACADEMIC PRESS (2010)

THÔNG TIN CHUNG:

Tên sách: Bone Cancer (tạm dịch: Ung thư xương).

Tác giả: Dominique Heymann.

NXB: Elsevier Academic Press (2010).

Thông số: 457 trang - 42 chương chính.

Ung thư xương là một trong những căn bệnh ung thư nguy hiểm, bệnh diễn tiến âm thầm và cướp đi sinh mạng của nhiều người; thông thường ung thư xương là do di căn từ các bộ phận ung thư khác. Cuốn sách này là những đúc kết kiến thức và kinh nghiệm sâu sắc nhất trong chẩn đoán và điều trị căn bệnh này, rất phù hợp đối với các học viên cũng như chuyên gia trong chuyên ngành có nhu cầu tiếp thu những kiến thức tiên tiến nhất. Sách bản đẹp, mục lục tự động, dung lượng nhỏ gọn, tương thích tốt với các thiết bị cầm tay.

INTRODUCTION (GIỚI THIỆU):

The past decade has witnessed an explosion in the field of bone biology. The topic of bone biology over this period has been marked by significant advances that have opened up entirely new areas for investigation. Indeed, the molecular mechanisms that control bone remodeling have been exten-sively investigated and some scientific fields have emerged. This is the case for osteoimmunology after identification of a set of molecules, allowing communication between bone cells (ostoclasts, osteoblasts) and immune cells (monocytes, lymphocytes, dendritic cells). Similarly, concepts based on the neuronal regulation of bone mass have emerged. Unfortunately, genetic or environmental deregulations lead to the development of bone cancer diseases such as primary bone tumors (osteosarcoma, Ewing’s sarcoma, chondrosar-comas, giant cell tumors, etc.) that originate from bone cells or from mesenchymal stem cells. Bone is also a privileged site for metastases due to the migration and development of tumor cells derivating from non-bone cells such as breast cancer cells or prostate carcinomas cells. Some tumor cells such as myeloma cells initially proliferate in bone sites and then induce a deregulation of the bone apposition and resorption balance in favor of an osteolytic process.

This book gives an overview of the most up-to-date epidemiological data of these tumors and their biology includ-ing molecular aspects (protein and gene) allowing clear identification of new therapeutic targets and approaches. As well as the biological aspects of bone tissue, primitive bone tumors and bone metastases well described in this book, the clinical aspects are also addressed: histopathol-ogy, imaging of bone tumors, management of bone pain and conventional therapeutic care. Finally, better understand-ing of biological mechanisms associated with the develop-ment of many pre-clinical models allows the emergence of new therapeutic approaches of bone tumors. Therefore, this book, describing bone tumors, from their fundamental aspects to their clinical aspects, is specifically dedicated to medical students and scientists, to health professionals, researchers and teachers working in the osteo-articular domain and interested in the more recent data available. This review book consists of 38 chapters resulting from the work of 26 professional teams from 11 countries and who are specializing in the pathophysiology of bone. I would like to thank the authors for the work performed and to give their expertise to the students, to our colleagues and to  all readers.

TABLE OF CONTENTS (MỤC LỤC):

Section I: Epidemiology and Economical Aspects of Bone Cancer

Section II: Bone Microenvironment and Bone Cancer

Section III: Bone Markers of Cancer (Genes and Proteins)

Section IV: Histopathology of Primary Bone Tumors and Bone Metastases

Section V: Imaging of Bone Cancer

Section VI: Pain Control in Bone Cancer

Section VII: New Therapeutic Advances in Primary Bone Cancers and Bone Metastases

TABLE OF CONTENTS (MỤC LỤC):

1. H. D. Dorfman, B. Czerniak, R. Kotz, D. Vanel, Y. K. Park & K. K. Unni, WHO classification of tumors of bone: Introduction, in: C. D. M. Fletcher, K. K. Unni & F. Mertens (Eds.) World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Soft Tissue and Bone, IARC Press, Lyon, 2002, pp. 226–232.

2. H. Van den Berg, A. Slaar, H. M. Kroon, A. H. Taminiau & P. Hogendoorn, Results of diagnostic review in pediatric bone tumors and tumorlike lesions, J Pediatr Orthop 28 (5) (2008)561–564.

3. E. I. Hauben, J. Arends, J. P. Vandenbroucke, C. J. Van Asperen, E. Van Marck & P. C. Hogendoorn, Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma, Eur J Hum Genet 11 (8) (2003)611–618.

4. L. Hameetman, J. V. M. G. Bovée, A. H. M. Taminiau, H. M. Kroon & P. C. W. Hogendoorn, Multiple osteochondromas: Clinicopathological and genetic spectrum and suggestions for clinical management, Hereditary Cancer in Clinical Practice 2 (4) (2004)161–173.

5. F. Mertens & K. K. Unni, Enchondromatosis: Ollier disease and Maffucci syndrome, in: C. D. M. Fletcher, K. K. Unni & F. Mertens (Eds.) World Health Organization Classification of Tumors. Pathology and genetics of tumors of soft tissue and bone, IARC Press, Lyon, 2002, pp. 356–357.

6. H. S. Schwartz, N. B. Zimmerman, M. A. Simon, R. R. Wroble, E. A. Millar & M. Bonfiglio, The malignant potential of enchondromatosis, J Bone Joint Surg Am 69 (2) (1987)269–274.

7. K. K. Unni & D. C. Dahlin, Premalignant tumors and conditions of bone, Am J Surg Pathol 3 (1) (1979)47–60.

8. R. Amin & R. Ling, Malignant fibrous histiocytoma following radiation therapy of fibrous dysplasia, Br J Radiol 68 (1995)1119–1122.

9. W. K. Taconis, Osteosarcoma in fibrous dysplasia, Skeletal Radiol 17 (1988)163–170.

10. J. D. Mulder, H. E. Schütte, H. M. Kroon & W. K. Taconis, Radiologic Atlas of Bone Tumors, 2nd ed., Elsevier, Amsterdam, 1993.

11. A. G. Huvos, Bone Tumors. Diagnosis, Treatment, and Prognosis, 2nd ed., W. B. Saunders Company, Philadelphia, 1991.

12. Dahlin’s Bone Tumors General Aspects and Data on 11,087 Cases. 5th ed. Philadelphia: Lippincott-Raven Publishers,1996.

13. H. Van den Berg, H. M. Kroon, A. Slaar & P. Hogendoorn, Incidence of biopsy-proven bone tumors in children: A report based on the Dutch pathology registration ‘PALGA’, J Pediatr Orthop 28 (1) (2008)29–35.

14. J. V. M. G. Bovee, A. M. Cleton-Jansen, A. H. M. Taminiau & P. C. W. Hogendoorn, Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment, Lancet Oncology 6 (8) (2005)599–607.

15. S. Ushigome, R. Machinami & P. H. Sorensen, Ewing sarcoma/ primitive neuroectodermal tumor (PNET), in: C. D. M. Fletcher, K. K. Unni & F. Mertens (Eds.) World Health Organization Classification of Tumors; Pathology & Genetics; Tumors of Soft Tissue and Bone, IARC Press, Lyon, 2002, pp. 298–300.

16. W. Guo, W. Xu, A. G. Huvos, J. H. Healey & C. Feng, Comparative frequency of bone sarcomas among different racial groups, Chin Med J (Engl) 112 (12) (1999)1101–1104.

17. L. F. Oudenhoven, E. Dhondt, S. Kahn, A. Nieborg, H. M. Kroon & P. C. Hogendoorn, et al., Accuracy of radiography in grading and tissue-specific diagnosis—a study of 200 consecutive bone tumors of the hand, Skeletal Radiol 35 (2) (2006)78–87.

18. K. J. Van Zwieten, P. Brys, F. Van Rietvelde, L. Oudenhoven, F. Vanhoenacker & F. Willemssens, et al., Imaging of the hand, techniques and pathology: A pictorial essay, JBR-BTR 90 (5) (2007)395–455.

19. A. Hadjipavlou, P. Lander, H. Srolovitz & I. P. Enker, Malignant transformation in Paget disease of bone, Cancer 70 (1992)2802–2808.

20. A. G. Huvos, A. Butler & S. Bretsky, Osteogenic sarcoma associated with Paget’s disease of bone. A clinicopathologic study of 65 patients, Cancer 52 (1983)1489–1495.

21. A. Giunti & M. Laus, Malignant tumors in chronic osteomyelitis. (A report of thirty nine cases, twenty six with long term follow up), Ital J Orthop Traumatol 4 (2) (1978)171–182.

22. C. Rubino, A. Shamsaldin, M. G. Le, M. Labbe, J. M. Guinebretiere & J. Chavaudra, et al., Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment, Breast Cancer Res Treat 89 (3) (2005)277–288.

23. A. G. Huvos & H. Q. Woodard, Postradiation sarcomas of bone, Health Phys 55 (4) (1988)631–636.

24. Y. M. Kirova, H. Rafi, M. C. Voisin, C. Rieux, M. Kuentz & S. L. Mouel, et al., Radiation-induced bone sarcoma following total body irradiation: Role of additional radiation on localized areas, Bone Marrow Transplant 25 (9) (2000)1011–1013.

25. G. F. Domson, A. Shahlaee, J. D. Reith, C. H. Bush & C. P. Gibbs, Infarct-associated bone sarcomas, Clin Orthop Relat Res 20 (2009).

26. W. J. Gillespie, C. M. Frampton, R. J. Henderson & P. M. Ryan, The incidence of cancer following total hip replacement, J Bone Joint Surg Br 70 (4) (1988)539–542.

27. B. A. Berrettoni & J. R. Carter, Mechanisms of cancer metastasis to bone, J Bone Joint Surg Am 68 (2) (1986)308–312.

28. D. L. Xu, X. T. Zhang, G. H. Wang, F. B. Li & J. Y. Hu, Clinical features of pathologically confirmed metastatic bone tumors— a report of 390 cases, Ai Zheng 24 (11) (2005)1404–1407.

29. S. Desai & N. Jambhekar, Clinicopathological evaluation of metastatic carcinomas of bone: A retrospective analysis of 114 cases over 10 years, Indian J Pathol Microbiol 38 (1) (1995)49–54.

30. R. E. Coleman, Skeletal complications of malignancy, Cancer 80 (8 Suppl) (1997)1588–1594.

31. L. S. Rosen, D. Gordon, S. Tchekmedyian, R. Yanagihara, V. Hirsh & M. Krzakowski, et al., Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group, J Clin Oncol 21 (16) (2003)3150–3157.

32. M. L. Brown, J. Lipscomb & C. Snyder, The burden of illness of cancer: Economic cost and quality of life, Annu Rev Public Health 22 (2001)91–113.

33. Cost Analysis: Cost of illness, CDC Econ Eval Tutorials (E), http: // cdc. Gov/owcd. EET/cost/fixed/3. Html

34. M. T. Groot, C. G. Boeken Kruger, R. C. Pelger & C. A. Uyl-de Groot, Costs of prostate cancer, metastatic to the bone, in the Netherlands, Eur Urol 43 (3) (2003)226–232.

35. T. Delea, C. Langer, J. McKiernan, M. Liss, J. Edelsberg & J. Brandman, et al., The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer, Oncology 67 (5–6) (2004)390–396.

36. T. E. Delea, J. McKiernan, J. Brandman, J. Edelsberg, J. Sung & M. Raut, et al., Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer, J Thorac Oncol 1 (6) (2006)571–576.

37. T. Delea, J. McKiernan, J. Brandman, J. Edelsberg, J. Sung & M. Raut, et al., Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice, J Support Oncol 4 (7) (2006)341–347.

38. N. Kinnane, Burden of bone disease, Eur J Oncol Nurs 11 (Suppl 2) (2007) S₂8–S₃1.

39. P. Major, Optimal management of metastatic bone disease, Eur J Oncol Nurs 11 (Suppl 2) (2007) S₃2–S₃7.

40. K. L. Schulman & J. Kohles, Economic burden of metastatic bone disease in the US, Cancer 109 (11) (2007)2334–2342.

41. J. Felix, V. Andreozzi, M. Soares, H. Gervasio, A. Moreira & L. Costa, et al., Direct hospital costs of skeletal-related events in Portuguese patients with breast cancer and bone metastases, J Clin Oncol 25 (18S) (2007)17084.

42. M. J. Lage, B. L. Barber, D. J. Harrison & S. Jun, The cost of treating skeletal-related events in patients with prostate cancer, Am J Manag Care 14 (5) (2008)317–322.

Download Ebook: BONE CANCER

========================